01643nas a2200481   4500000000100000000000100001000000100002008004100003653006300044653005800107653005600165653005300221653001200274653003200286653002000318653001100338653002700349653002400376653006100400653002600461653001100487653006100498653001600559653003200575653002700607653001900634653001800653653002700671653003700698653001800735100001300753700001300766700001300779700001200792700001400804700001600818700001400834245024600848250001501094300001401109490000701123020003101130       2021                            d10a*Cardiovascular Diseases/epidemiology/prevention & control10a*Diabetes Mellitus, Type 2/complications/drug therapy10a*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use10aDipeptidyl-Peptidases and Tripeptidyl-Peptidases10aGlucose10a*Heart Failure/epidemiology10aHospitalization10aHumans10a*Myocardial Infarction10aPrimary health care10a*Renal Insufficiency, Chronic/complications/epidemiology10aRetrospective Studies10aSodium10a*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use10a*Symporters10aUnited Kingdom/epidemiology10aCardiovascular disease10aclinical trial10adapagliflozin10adiabetes complications10adipeptidyl peptidase-4 inhibitor10aheart failure1 aI. Idris1 aR. Zhang1 aJ. Mamza1 aM. Ford1 aT. Morris1 aA. Banerjee1 aK. Khunti00aLower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease  a2021/05/12  a2207-22140 v23  a1462-8902 (Print)1462-8902